- ホーム
- > 洋書
- > 英文書
- > Science / Mathematics
Full Description
This book is the first text to provide a comprehensive assessment of the application of fundamental principles of dissolution and drug release testing to poorly soluble compounds and formulations. Such drug products are, vis-à-vis their physical and chemical properties, inherently incompatible with aqueous dissolution. However, dissolution methods are required for product development and selection, as well as for the fulfillment of regulatory obligations with respect to biopharmaceutical assessment and product quality understanding. The percentage of poorly soluble drugs, defined in classes 2 and 4 of the Biopharmaceutics Classification System (BCS), has significantly increased in the modern pharmaceutical development pipeline. This book provides a thorough exposition of general method development strategies for such drugs, including instrumentation and media selection, the use of compendial and non-compendial techniques in product development, and phase-appropriate approaches to dissolution development.
Emerging topics in the field of dissolution are also discussed, including biorelevant and biphasic dissolution, the use on enzymes in dissolution testing, dissolution of suspensions, and drug release of non-oral products. Of particular interest to the industrial pharmaceutical professional, a brief overview of the formulation and solubilization techniques employed in the development of BCS class 2 and 4 drugs to overcome solubility challenges is provided and is complemented by a collection of chapters that survey the approaches and considerations in developing dissolution methodologies for enabling drug delivery technologies, including nanosuspensions, lipid-based formulations, and stabilized amorphous drug formulations.
Contents
Introduction. Solubility determination for pharmaceutical API. Use of surfactants in dissolution testing. Intrinsic dissolution evaluation of poorly soluble drugs. Oral delivery of poorly soluble drugs. A staged approach to pharmaceutical dissolution testing. Development and application of in vitro two-phase dissolution method for poorly water soluble drugs. The use of Apparatus 3 in dissolution testing of poorly soluble drug formulations. Use of Apparatus 4 in dissolution testing, including sparingly and poorly soluble drugs. Dissolution of nanoparticle drug formulations. Dissolution of lipid based drug formulations. Dissolution of stabilized amorphous drug formulations. Dissolution of pharmaceutical suspensions. Dissolution testing of poorly soluble drugs: 'Biorelevant dissolution'. Clinically relevant dissolution for low solubility immediate release products. The QbD approach to method development and validation for dissolution testing. Regulatory considerations in dissolution and drug release of BCS class II and IV compounds. Dissolution of liquid-filled capsules based formulations. Current and emerging non-compendial methods for dissolution testing.
